Table 2 Agents for initial treatment of non-squamous stage IV NSCLCs
Agents | Toyama | Ishikawa | Fukui | Nagano | Hokushin region |
|---|---|---|---|---|---|
Cases (%) | Cases (%) | Cases (%) | Cases (%) | Cases (%) | |
EGFR-TKIs | 67 (44.1%) | 60 (42.0%) | 18 (27.7%) | 60 (40.0%) | 205 (39.3%) |
ALK inhibitor | 5 (3.1%) | 9 (6.3%) | 2 (3.1%) | 5 (3.3%) | 21 (4.0%) |
ICIs | 19 (11.7%) | 15 (10.5%) | 5 (7.7%) | 14 (9.3%) | 53 (10.2%) |
Platinum compound | 61 (37.4%) | 39 (27.3%) | 37 (56.9%) | 65 (43.3%) | 202 (38.8%) |
Non-platinum | 11 (6.7%) | 20 (14.0%) | 3 (4.6%) | 6 (4.0%) | 40 (7.7%) |
Total | 163 | 143 | 65 | 150 | 521 |